Are you over 18 and want to see adult content?
More Annotations
A complete backup of secrets-center.ru
Are you over 18 and want to see adult content?
A complete backup of alan-greenman.tumblr.com
Are you over 18 and want to see adult content?
A complete backup of businessingmag.com
Are you over 18 and want to see adult content?
A complete backup of ciadalogo.com.br
Are you over 18 and want to see adult content?
A complete backup of graffitiwallpaper.com
Are you over 18 and want to see adult content?
A complete backup of trendzone.com.ng
Are you over 18 and want to see adult content?
A complete backup of fullmetalalchemistrpggame.blogspot.com
Are you over 18 and want to see adult content?
A complete backup of exportaward.com.au
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of tortugabackpacks.com
Are you over 18 and want to see adult content?
A complete backup of motherandbaby.co.uk
Are you over 18 and want to see adult content?
A complete backup of scottysgolfgrip.com
Are you over 18 and want to see adult content?
A complete backup of merchantsofdoubt.org
Are you over 18 and want to see adult content?
A complete backup of findagroomer.com
Are you over 18 and want to see adult content?
A complete backup of digitalinnovations.com
Are you over 18 and want to see adult content?
Text
you
ACTIVATING THE IMMUNE SYSTEM :: HEAT BIOLOGICS, INC. (HTBX)NEWS / EVENTSABOUTTECHNOLOGYPRODUCT PIPELINEINVESTORSNEWS & MEDIA Activating the Immune System. Our proprietary gp96 platform activates the human immune system to combat cancer and infectious disease. Heat Biologics is developing a robust pipeline of first-in-class products that activate and / or modulate the immune system. Our Technologies Our Product Pipeline. PRODUCT PIPELINE :: HEAT BIOLOGICS, INC. (HTBX) Heat Biologics a biopharmaceutical company that develops immunotherapies with the goal of activating a patient's immune system against cancer through T-cell activation. Our proprietary, T-cell Activation Platform (TCAP) produces POSITIVE SURVIVAL DATA FROM PHASE 2 LUNG CANCER TRIAL Heat Biologics a biopharmaceutical company that develops immunotherapies with the goal of activating a patient's immune system against cancer through T-cell activation. Our proprietary, T-cell Activation Platform (TCAP) produces PTX-35 :: HEAT BIOLOGICS, INC. (HTBX) PTX-35 is a potential first-in-class T cell co-stimulator targeting TNFRSF25 (Death Receptor 3). Favorable safety profile was demonstrated in mice and non-human primates. PTX-35’s development plan focuses on cancer immunotherapy. Pelican has been awarded a $15.2 million Cancer Prevention Institute of Texas (CPRIT) grant (the “CPRIT Grant ANNUAL REPORTS :: HEAT BIOLOGICS, INC. (HTBX) Heat Biologics a biopharmaceutical company that develops immunotherapies with the goal of activating a patient's immune system against cancer through T-cell activation. Our proprietary, T-cell Activation Platform (TCAP) produces HS-110 :: HEAT BIOLOGICS, INC. (HTBX) HS-110 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer. Our HS-110 Phase 2, multicenter clinical trial is evaluating the safety and efficacy of HS-110 in combination with Bristol-Myers Squibb’s checkpoint inhibitor, nivolumab (Opdivo®) or Merck’s checkpoint inhibitor, pembrolizumab (Keytruda®). HEAT BIOLOGICS COMMENCES MANUFACTURING PROCESS FOR ZVX-60 Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company's gp96 platform is designed to activate immune responses against cancer or pathogenic antigens. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which HEAT BIOLOGICS ANNOUNCES PROMISING SURVIVAL DATA OF HS-110 DURHAM, N.C., May 20, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that the latest data from HS-110, the Company’s lead product, has been accepted for poster presentation at the 2021 American Society of Clinical Oncology (ASCO) HEAT BIOLOGICS ANNOUNCES COMPLETION OF ACQUISITION OF Acquisition Brings $15.2 Million CPRIT Grant to Fund 70-Patient Phase 1 Trial. DURHAM, NC / ACCESSWIRE / May 1, 2017 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a leader in the development of immunotherapies designed to activate a patient's immune system against cancer, announced that the company has completed the acquisition of an 80% controlling interest in Pelican Therapeutics, Inc AMENDMENT TO OFFER LETTER This Amendment (this “ Amendment ”), effective as of January 4, 2021, amends the offer letter, dated September 23, 2019, as amended January 1, 2020 (the “ Offer Letter ”), and is entered into by and between Heat Biologics, Inc. (the “ Company ”) and William Ostrander. Effective as of the date hereof, the Company has appointedyou
PRODUCT PIPELINE :: HEAT BIOLOGICS, INC. (HTBX) Heat Biologics a biopharmaceutical company that develops immunotherapies with the goal of activating a patient's immune system against cancer through T-cell activation. Our proprietary, T-cell Activation Platform (TCAP) produces HS-110 :: HEAT BIOLOGICS, INC. (HTBX) HS-110 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer. Our HS-110 Phase 2, multicenter clinical trial is evaluating the safety and efficacy of HS-110 in combination with Bristol-Myers Squibb’s checkpoint inhibitor, nivolumab (Opdivo®) or Merck’s checkpoint inhibitor, pembrolizumab (Keytruda®). CAREERS :: HEAT BIOLOGICS, INC. (HTBX) Career Opportunities. Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company's gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96platform
INVESTOR RELATIONS :: HEAT BIOLOGICS, INC. (HTBX) Heat Biologics a biopharmaceutical company that develops immunotherapies with the goal of activating a patient's immune system against cancer through T-cell activation. Our proprietary, T-cell Activation Platform (TCAP) produces therapies designed to turn "cold" tumors "hot," and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase effectiveness. HS-130 :: HEAT BIOLOGICS, INC. (HTBX) HS-130 is the company’s allogeneic (“off-the-shelf”) cell line engineered to express OX40 ligand fusion protein (OX40L-Fc). OX40 ligand is a key co-stimulator of T cells that augments antigen-specific CD8+ T cell responses. Improved efficacy and safety were demonstrated in multiple preclinical cancer models using OX40L-Fcvia cell-based
HEAT BIOLOGICS ANNOUNCES RESEARCH COLLABORATION WITH Heat Biologics a biopharmaceutical company that develops immunotherapies with the goal of activating a patient's immune system against cancer through T-cell activation. Our proprietary, T-cell Activation Platform (TCAP) produces HEAT BIOLOGICS ANNOUNCES PROMISING SURVIVAL DATA OF HS-110 DURHAM, N.C., May 20, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that the latest data from HS-110, the Company’s lead product, has been accepted for poster presentation at the 2021 American Society of Clinical Oncology (ASCO) HEAT BIOLOGICS PROVIDES BUSINESS UPDATE :: HEAT BIOLOGICS Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The Company's gp96 platform is designed to activate immune responses against cancer or pathogenic antigens. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which HEAT BIOLOGICS ANNOUNCES FIRST PATIENT DOSED IN THE FIRST Heat Biologics a biopharmaceutical company that develops immunotherapies with the goal of activating a patient's immune system against cancer through T-cell activation. Our proprietary, T-cell Activation Platform (TCAP) produces HEAT BIOLOGICS TO SHOWCASE FAVORABLE SURVIVAL DATA OF HS Survival benefit observed in two treatment settings of previously treated non-small lung cancer patients. DURHAM, N.C., June 04, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that Dr. Roger B. Cohen, MD, Professor of Medicine at theUniversity
ACTIVATING THE IMMUNE SYSTEM :: HEAT BIOLOGICS, INC. (HTBX)NEWS / EVENTSABOUTTECHNOLOGYPRODUCT PIPELINEINVESTORSNEWS & MEDIA Activating the Immune System. Our proprietary gp96 platform activates the human immune system to combat cancer and infectious disease. Heat Biologics is developing a robust pipeline of first-in-class products that activate and / or modulate the immune system. Our Technologies Our Product Pipeline. COVID-19 VACCINE :: HEAT BIOLOGICS, INC. (HTBX) The company initiated a COVID-19 vaccine collaboration with the University of Miami in March 2020. Heat Biologics’ COVID-19 vaccine program focuses on engineering multiple protein regions of the virus into our gp96 platform. Such design has the potential of generating long-term immune responses and may confer immunity to differentcoronaviruses.
NEWS RELEASES :: HEAT BIOLOGICS, INC. (HTBX) Heat Biologics Announces New Preclinical Data on PTX-35, Demonstrating Decreased Regulatory T-cell (Treg) Activity and Delayed Tumor Progression at American Association for Cancer Research (AACR) Annual Meeting 2021. Apr 12, 2021. PRODUCT PIPELINE :: HEAT BIOLOGICS, INC. (HTBX) Heat Biologics a biopharmaceutical company that develops immunotherapies with the goal of activating a patient's immune system against cancer through T-cell activation. Our proprietary, T-cell Activation Platform (TCAP) produces INVESTOR RELATIONS :: HEAT BIOLOGICS, INC. (HTBX) Heat Biologics a biopharmaceutical company that develops immunotherapies with the goal of activating a patient's immune system against cancer through T-cell activation. Our proprietary, T-cell Activation Platform (TCAP) produces therapies designed to turn "cold" tumors "hot," and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase effectiveness. PTX-35 :: HEAT BIOLOGICS, INC. (HTBX) PTX-35 is a potential first-in-class T cell co-stimulator targeting TNFRSF25 (Death Receptor 3). Favorable safety profile was demonstrated in mice and non-human primates. PTX-35’s development plan focuses on cancer immunotherapy. Pelican has been awarded a $15.2 million Cancer Prevention Institute of Texas (CPRIT) grant (the “CPRIT Grant HS-110 :: HEAT BIOLOGICS, INC. (HTBX) HS-110 is an off-the-shelf cell-based therapy. Our scientists have genetically engineered HS-110 to secrete a wide range of cancer testis antigens chaperoned by gp96 proteins. In clinical trials, HS-110 demonstrated a broad activation of T-cell mediated immune response incancer patients.
HEAT BIOLOGICS COMMENCES MANUFACTURING PROCESS FOR ZVX-60 Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company's gp96 platform is designed to activate immune responses against cancer or pathogenic antigens. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which HS-130 :: HEAT BIOLOGICS, INC. (HTBX) HS-130 is the company’s allogeneic (“off-the-shelf”) cell line engineered to express OX40 ligand fusion protein (OX40L-Fc). OX40 ligand is a key co-stimulator of T cells that augments antigen-specific CD8+ T cell responses. Improved efficacy and safety were demonstrated in multiple preclinical cancer models using OX40L-Fcvia cell-based
ANALYST COVERAGE :: HEAT BIOLOGICS, INC. (HTBX) Analyst Coverage. Heat Biologics, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Heat Biologics, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts orpredictions of
ACTIVATING THE IMMUNE SYSTEM :: HEAT BIOLOGICS, INC. (HTBX)NEWS / EVENTSABOUTTECHNOLOGYPRODUCT PIPELINEINVESTORSNEWS & MEDIA Activating the Immune System. Our proprietary gp96 platform activates the human immune system to combat cancer and infectious disease. Heat Biologics is developing a robust pipeline of first-in-class products that activate and / or modulate the immune system. Our Technologies Our Product Pipeline. COVID-19 VACCINE :: HEAT BIOLOGICS, INC. (HTBX) The company initiated a COVID-19 vaccine collaboration with the University of Miami in March 2020. Heat Biologics’ COVID-19 vaccine program focuses on engineering multiple protein regions of the virus into our gp96 platform. Such design has the potential of generating long-term immune responses and may confer immunity to differentcoronaviruses.
NEWS RELEASES :: HEAT BIOLOGICS, INC. (HTBX) Heat Biologics Announces New Preclinical Data on PTX-35, Demonstrating Decreased Regulatory T-cell (Treg) Activity and Delayed Tumor Progression at American Association for Cancer Research (AACR) Annual Meeting 2021. Apr 12, 2021. PRODUCT PIPELINE :: HEAT BIOLOGICS, INC. (HTBX) Heat Biologics a biopharmaceutical company that develops immunotherapies with the goal of activating a patient's immune system against cancer through T-cell activation. Our proprietary, T-cell Activation Platform (TCAP) produces INVESTOR RELATIONS :: HEAT BIOLOGICS, INC. (HTBX) Heat Biologics a biopharmaceutical company that develops immunotherapies with the goal of activating a patient's immune system against cancer through T-cell activation. Our proprietary, T-cell Activation Platform (TCAP) produces therapies designed to turn "cold" tumors "hot," and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase effectiveness. PTX-35 :: HEAT BIOLOGICS, INC. (HTBX) PTX-35 is a potential first-in-class T cell co-stimulator targeting TNFRSF25 (Death Receptor 3). Favorable safety profile was demonstrated in mice and non-human primates. PTX-35’s development plan focuses on cancer immunotherapy. Pelican has been awarded a $15.2 million Cancer Prevention Institute of Texas (CPRIT) grant (the “CPRIT Grant HS-110 :: HEAT BIOLOGICS, INC. (HTBX) HS-110 is an off-the-shelf cell-based therapy. Our scientists have genetically engineered HS-110 to secrete a wide range of cancer testis antigens chaperoned by gp96 proteins. In clinical trials, HS-110 demonstrated a broad activation of T-cell mediated immune response incancer patients.
HEAT BIOLOGICS COMMENCES MANUFACTURING PROCESS FOR ZVX-60 Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company's gp96 platform is designed to activate immune responses against cancer or pathogenic antigens. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which HS-130 :: HEAT BIOLOGICS, INC. (HTBX) HS-130 is the company’s allogeneic (“off-the-shelf”) cell line engineered to express OX40 ligand fusion protein (OX40L-Fc). OX40 ligand is a key co-stimulator of T cells that augments antigen-specific CD8+ T cell responses. Improved efficacy and safety were demonstrated in multiple preclinical cancer models using OX40L-Fcvia cell-based
ANALYST COVERAGE :: HEAT BIOLOGICS, INC. (HTBX) Analyst Coverage. Heat Biologics, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Heat Biologics, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts orpredictions of
COVID-19 VACCINE :: HEAT BIOLOGICS, INC. (HTBX) The company initiated a COVID-19 vaccine collaboration with the University of Miami in March 2020. Heat Biologics’ COVID-19 vaccine program focuses on engineering multiple protein regions of the virus into our gp96 platform. Such design has the potential of generating long-term immune responses and may confer immunity to differentcoronaviruses.
ABOUT :: HEAT BIOLOGICS, INC. (HTBX) About Us. Heat Biologics, Inc (NASDAQ: HTBX) is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company's gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96 CAREERS :: HEAT BIOLOGICS, INC. (HTBX) Career Opportunities. Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company's gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96platform
EXPANDED ACCESS :: HEAT BIOLOGICS, INC. (HTBX) Expanded Access and Compassionate Use of Investigational Medicines. At Heat Biologics, we are committed to developing safe and effective immunotherapies for a wide range of cancers and believe that participation in clinical trials is the most appropriate way to access our investigational therapies. ANNUAL REPORTS :: HEAT BIOLOGICS, INC. (HTBX) Heat Biologics a biopharmaceutical company that develops immunotherapies with the goal of activating a patient's immune system against cancer through T-cell activation. Our proprietary, T-cell Activation Platform (TCAP) produces POSITIVE SURVIVAL DATA FROM PHASE 2 LUNG CANCER TRIAL Heat Biologics a biopharmaceutical company that develops immunotherapies with the goal of activating a patient's immune system against cancer through T-cell activation. Our proprietary, T-cell Activation Platform (TCAP) produces HEAT BIOLOGICS APPOINTS ANTHONY MANNING, PH.D. AS CHIEF DURHAM, N.C., May 10, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announced the appointment of Anthony Manning, Ph.D. as Chief Scientific Advisor. HEAT BIOLOGICS ANNOUNCES PROMISING SURVIVAL DATA OF HS-110 DURHAM, N.C., May 20, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that the latest data from HS-110, the Company’s lead product, has been accepted for poster presentation at the 2021 American Society of Clinical Oncology (ASCO) HEAT BIOLOGICS AND UNIVERSITY OF MIAMI DEVELOPING Test being designed to provide rapid, point-of-care diagnosis within 30 minutes. DURHAM, NC / ACCESSWIRE / March 23, 2020 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a clinical-stage biopharmaceutical company specialized in the development of novel therapeutic and prophylactic vaccines, including one for coronavirus COVID-19, today reported that it is collaborating with the HEAT BIOLOGICS ANNOUNCES COMPLETION OF ACQUISITION OF Acquisition Brings $15.2 Million CPRIT Grant to Fund 70-Patient Phase 1 Trial. DURHAM, NC / ACCESSWIRE / May 1, 2017 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a leader in the development of immunotherapies designed to activate a patient's immune system against cancer, announced that the company has completed the acquisition of an 80% controlling interest in Pelican Therapeutics, Inc ACTIVATING THE IMMUNE SYSTEM :: HEAT BIOLOGICS, INC. (HTBX)NEWS / EVENTSABOUTTECHNOLOGYPRODUCT PIPELINEINVESTORSNEWS & MEDIA Activating the Immune System. Our proprietary gp96 platform activates the human immune system to combat cancer and infectious disease. Heat Biologics is developing a robust pipeline of first-in-class products that activate and / or modulate the immune system. Our ABOUT :: HEAT BIOLOGICS, INC. (HTBX) About Us. Heat Biologics, Inc (NASDAQ: HTBX) is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company's gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96 PRODUCT PIPELINE :: HEAT BIOLOGICS, INC. (HTBX) Heat Biologics a biopharmaceutical company that develops immunotherapies with the goal of activating a patient's immune system against cancer through T-cell activation. Our proprietary, T-cell Activation Platform (TCAP) produces NEWS RELEASES :: HEAT BIOLOGICS, INC. (HTBX) Heat Biologics Announces New Preclinical Data on PTX-35, Demonstrating Decreased Regulatory T-cell (Treg) Activity and Delayed Tumor Progression at American Association for Cancer Research (AACR) Annual Meeting 2021. Apr 12, 2021. INVESTOR RELATIONS :: HEAT BIOLOGICS, INC. (HTBX) Heat Biologics a biopharmaceutical company that develops immunotherapies with the goal of activating a patient's immune system against cancer through T-cell activation. Our proprietary, T-cell Activation Platform (TCAP) produces therapies designed to turn "cold" tumors "hot," and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase effectiveness. POSITIVE SURVIVAL DATA FROM PHASE 2 LUNG CANCER TRIAL Heat Biologics a biopharmaceutical company that develops immunotherapies with the goal of activating a patient's immune system against cancer through T-cell activation. Our proprietary, T-cell Activation Platform (TCAP) produces PTX-35 :: HEAT BIOLOGICS, INC. (HTBX) PTX-35 is a potential first-in-class T cell co-stimulator targeting TNFRSF25 (Death Receptor 3). Favorable safety profile was demonstrated in mice and non-human primates. PTX-35’s development plan focuses on cancer immunotherapy. Pelican has been awarded a $15.2 million Cancer Prevention Institute of Texas (CPRIT) grant (the “CPRIT Grant CAREERS :: HEAT BIOLOGICS, INC. (HTBX) Career Opportunities. Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company's gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96platform
HS-130 :: HEAT BIOLOGICS, INC. (HTBX) HS-130 is the company’s allogeneic (“off-the-shelf”) cell line engineered to express OX40 ligand fusion protein (OX40L-Fc). OX40 ligand is a key co-stimulator of T cells that augments antigen-specific CD8+ T cell responses. Improved efficacy and safety were demonstrated in multiple preclinical cancer models using OX40L-Fcvia cell-based
AMENDMENT TO OFFER LETTER This Amendment (this “ Amendment ”), effective as of January 4, 2021, amends the offer letter, dated September 23, 2019, as amended January 1, 2020 (the “ Offer Letter ”), and is entered into by and between Heat Biologics, Inc. (the “ Company ”) and William Ostrander. Effective as of the date hereof, the Company has appointedyou
ACTIVATING THE IMMUNE SYSTEM :: HEAT BIOLOGICS, INC. (HTBX)NEWS / EVENTSABOUTTECHNOLOGYPRODUCT PIPELINEINVESTORSNEWS & MEDIA Activating the Immune System. Our proprietary gp96 platform activates the human immune system to combat cancer and infectious disease. Heat Biologics is developing a robust pipeline of first-in-class products that activate and / or modulate the immune system. Our ABOUT :: HEAT BIOLOGICS, INC. (HTBX) About Us. Heat Biologics, Inc (NASDAQ: HTBX) is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company's gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96 PRODUCT PIPELINE :: HEAT BIOLOGICS, INC. (HTBX) Heat Biologics a biopharmaceutical company that develops immunotherapies with the goal of activating a patient's immune system against cancer through T-cell activation. Our proprietary, T-cell Activation Platform (TCAP) produces NEWS RELEASES :: HEAT BIOLOGICS, INC. (HTBX) Heat Biologics Announces New Preclinical Data on PTX-35, Demonstrating Decreased Regulatory T-cell (Treg) Activity and Delayed Tumor Progression at American Association for Cancer Research (AACR) Annual Meeting 2021. Apr 12, 2021. INVESTOR RELATIONS :: HEAT BIOLOGICS, INC. (HTBX) Heat Biologics a biopharmaceutical company that develops immunotherapies with the goal of activating a patient's immune system against cancer through T-cell activation. Our proprietary, T-cell Activation Platform (TCAP) produces therapies designed to turn "cold" tumors "hot," and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase effectiveness. POSITIVE SURVIVAL DATA FROM PHASE 2 LUNG CANCER TRIAL Heat Biologics a biopharmaceutical company that develops immunotherapies with the goal of activating a patient's immune system against cancer through T-cell activation. Our proprietary, T-cell Activation Platform (TCAP) produces PTX-35 :: HEAT BIOLOGICS, INC. (HTBX) PTX-35 is a potential first-in-class T cell co-stimulator targeting TNFRSF25 (Death Receptor 3). Favorable safety profile was demonstrated in mice and non-human primates. PTX-35’s development plan focuses on cancer immunotherapy. Pelican has been awarded a $15.2 million Cancer Prevention Institute of Texas (CPRIT) grant (the “CPRIT Grant CAREERS :: HEAT BIOLOGICS, INC. (HTBX) Career Opportunities. Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company's gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96platform
HS-130 :: HEAT BIOLOGICS, INC. (HTBX) HS-130 is the company’s allogeneic (“off-the-shelf”) cell line engineered to express OX40 ligand fusion protein (OX40L-Fc). OX40 ligand is a key co-stimulator of T cells that augments antigen-specific CD8+ T cell responses. Improved efficacy and safety were demonstrated in multiple preclinical cancer models using OX40L-Fcvia cell-based
AMENDMENT TO OFFER LETTER This Amendment (this “ Amendment ”), effective as of January 4, 2021, amends the offer letter, dated September 23, 2019, as amended January 1, 2020 (the “ Offer Letter ”), and is entered into by and between Heat Biologics, Inc. (the “ Company ”) and William Ostrander. Effective as of the date hereof, the Company has appointedyou
TECHNOLOGY :: HEAT BIOLOGICS, INC. (HTBX) Heat Biologics’ Proprietary gp96 Platform. 1. Leverages gp96’s role as a natural molecular warning system. 2. Off-the-shelf allogeneic cell vaccine. 3. Broad applications in cancer treatment and vaccines for infectious diseases. 4. Lead product in a Phase 2 trial ABOUT :: HEAT BIOLOGICS, INC. (HTBX) About Us. Heat Biologics, Inc (NASDAQ: HTBX) is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company's gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96 CONTACT :: HEAT BIOLOGICS, INC. (HTBX) Heat Biologics a biopharmaceutical company that develops immunotherapies with the goal of activating a patient's immune system against cancer through T-cell activation. Our proprietary, T-cell Activation Platform (TCAP) produces HEAT BIOLOGICS TO SHOWCASE FAVORABLE SURVIVAL DATA OF HS Survival benefit observed in two treatment settings of previously treated non-small lung cancer patients. DURHAM, N.C., June 04, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that Dr. Roger B. Cohen, MD, Professor of Medicine at theUniversity
EXPANDED ACCESS :: HEAT BIOLOGICS, INC. (HTBX) Expanded Access and Compassionate Use of Investigational Medicines. At Heat Biologics, we are committed to developing safe and effective immunotherapies for a wide range of cancers and believe that participation in clinical trials is the most appropriate way to access our investigational therapies. HS-130 :: HEAT BIOLOGICS, INC. (HTBX) HS-130 is the company’s allogeneic (“off-the-shelf”) cell line engineered to express OX40 ligand fusion protein (OX40L-Fc). OX40 ligand is a key co-stimulator of T cells that augments antigen-specific CD8+ T cell responses. Improved efficacy and safety were demonstrated in multiple preclinical cancer models using OX40L-Fcvia cell-based
HEAT BIOLOGICS AND UNIVERSITY OF MIAMI DEVELOPING Test being designed to provide rapid, point-of-care diagnosis within 30 minutes. DURHAM, NC / ACCESSWIRE / March 23, 2020 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a clinical-stage biopharmaceutical company specialized in the development of novel therapeutic and prophylactic vaccines, including one for coronavirus COVID-19, today reported that it is collaborating with the HS-110 :: HEAT BIOLOGICS, INC. (HTBX) HS-110 is an off-the-shelf cell-based therapy. Our scientists have genetically engineered HS-110 to secrete a wide range of cancer testis antigens chaperoned by gp96 proteins. In clinical trials, HS-110 demonstrated a broad activation of T-cell mediated immune response incancer patients.
QUOTE - INVESTOR RELATIONS :: HEAT BIOLOGICS, INC. (HTBX) Heat Biologics a biopharmaceutical company that develops immunotherapies with the goal of activating a patient's immune system against cancer through T-cell activation. Our proprietary, T-cell Activation Platform (TCAP) produces MANAGEMENT TEAM :: HEAT BIOLOGICS, INC. (HTBX) Jeffrey Wolf. Jeffrey Wolf is founder and CEO of Heat Biologics. He also founded Seed-One Ventures, a firm focused on the systematic formation and management of new biomedical companies based upon breakthrough research. Throughout his career, Mr. Wolf has specialized in building new life-science companies from the ground up and hasplayed an
Twitter Facebook
* Home
* About
* Management Team
* Board of Directors * Scientific Advisory Board * Pelican Therapeutics* Technology
* gp96 Platform
* Pelican’s PTX-35 Co-stimulatory Antibody* Product Pipeline
* Overview
* HS-110
* HS-130
* COVID-19 Vaccine
* PTX-35
* Expanded Access
* Scientific Publications* Investors
* Overview
* News / Events
* Company Information * Financial Information* Stock Data
* SEC Filings
* Corporate Governance * Corporate Presentation* News & Media
* News Releases
* Events
* Careers
* Contact
ACTIVATING THE IMMUNE SYSTEM About Heat Biologics Go to Content ACTIVATING THE IMMUNE SYSTEM Our proprietary gp96 platform activates the human immune system to combat cancer and infectious disease. Heat Biologics is developing a robust pipeline of first-in-class products that activate and / or modulate the immune system. Our Technologies Our Product PipelineLATEST NEWS
Jun 4, 2021
HEAT BIOLOGICS TO SHOWCASE FAVORABLE SURVIVAL DATA OF HS-110 IN PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER PATIENTS AT 2021 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETINGRead More
May 20, 2021
HEAT BIOLOGICS ANNOUNCES PROMISING SURVIVAL DATA OF HS-110 IN TWO TREATMENT SETTINGS OF LUNG CANCER; SELECTED FOR PRESENTATION AT 2021 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETINGRead More
May 19, 2021
HEAT BIOLOGICS ANNOUNCES MULTIPLE PRESENTATIONS ON PTX-35 AT THE UPCOMING 3RD ANNUAL TREG DIRECTED THERAPIES SUMMITRead More
View all news View
Stock Information
EMAIL ALERTS
Stay informed and receive company updates straight to your inboxSign up today
First Name
Last Name
Email Address
Contact Type: Individual Investor Analyst Broker/Investment Advisor Portfolio Manager Banker/Financing Source Press/Media Consultant Employee Customer/Client Student OtherIndividual Investor
* Individual Investor* Analyst
* Broker/Investment Advisor* Portfolio Manager
* Banker/Financing Source* Press/Media
* Consultant
* Employee
* Customer/Client
* Student
* Other
Sign me up for:
Press Releases
Annual & Quarterly ReportsCurrent Reports
Insider TransactionsProxy Information
All Filings
Sign Up
2021 Heat Biologics, Inc. All Rights Reserved. Privacy Policy Disclaimer SitemapDetails
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0